UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
BIOTECHNOLOGY

Illumina

I

Illumina

BiotechnologySan Diego, United States
Visit Website

About Illumina

Illumina is the company that made whole-genome sequencing a routine laboratory tool, transforming what was once a decade-long, billion-dollar undertaking into an everyday clinical and research workflow. Founded in 1998 and headquartered in San Diego, California, Illumina develops and manufactures sequencing and array-based instruments, reagents, and informatics software used by researchers, hospitals, and public health agencies in more than 160 countries.

Sequencing Platforms & Instruments

The company's portfolio spans a wide range of output scales, from the compact iSeq 100 designed for low-throughput clinical applications to the NovaSeq X Series, capable of sequencing multiple human genomes per run. This breadth allows Illumina to serve single-investigator labs and national genomics programmes alike. The DRAGEN Bio-IT Platform provides on-board secondary analysis, accelerating the path from raw sequence data to actionable variant calls.

Clinical Genomics & Oncology Applications

Illumina's technology underpins a substantial portion of global next-generation sequencing activity in oncology, inherited disease, reproductive health, and infectious disease surveillance. Its instruments and kits are widely used for companion diagnostic development, rare disease diagnosis, non-invasive prenatal testing, and cancer genomic profiling. The company has also invested in multi-cancer early detection through its Grail subsidiary, which operates the Galleri liquid biopsy test.

Listed on NASDAQ under the ticker ILMN, Illumina is a large-cap life science tools company with revenues consistently in the multi-billion-dollar range. Its customer base includes academic research centres, pharmaceutical and biotechnology companies, contract research organisations, and national health services. The company has been central to landmark population genomics initiatives, including partnerships with the UK Biobank and various national sequencing programmes launched during the COVID-19 pandemic for viral surveillance.

Illumina operates manufacturing sites in San Diego and Singapore, with commercial offices across North America, Europe, and Asia-Pacific. Research and development investment has remained a defining feature of its business model, with ongoing work on short-read chemistry improvements and emerging long-read sequencing capabilities.

Further information is available at illumina.com.

Similar Companies

More in Biotechnology

E

Emergex

Emergex Vaccines is a UK-based clinical-stage biotechnology company developing a new class of synthetic peptide vaccines designed to stimulate cytotoxic T-lymphocyte (CTL) responses rather than the antibody-driven immunity targeted by conventional vaccines. Founded in 2015 and headquartered in Abingdon, Oxfordshire, the company was established on the premise that T-cell immunity offers broader and more durable protection against rapidly mutating viral pathogens, including pandemic influenza strains and other emerging infectious threats. Platform Technology and Pipeline The company's core platform centres on short synthetic peptide constructs derived from conserved viral protein sequences. Because these sequences change little across viral variants, the approach aims to produce vaccines with cross-strain efficacy, addressing a central limitation of seasonal influenza vaccines that must be reformulated annually. Emergex has advanced candidates targeting influenza A and dengue fever through early-phase clinical evaluation, with additional programmes directed at other flaviviruses and respiratory viruses. Development and Funding Background Emergex has received support from UK public funding bodies and private investors to progress its pipeline from pre-clinical research into Phase I clinical trials. The company operates under a largely asset-light model, collaborating with contract research organisations and academic partners to conduct clinical work. As a private company, Emergex does not carry a public stock listing. Its programmes are positioned within the broader landscape of next-generation vaccine development, addressing unmet needs in both seasonal infectious disease management and pandemic preparedness. Further information is available at emergexvaccines.com.

View profile
E

Elasmogen Ltd

Founded in Aberdeen, Scotland, Elasmogen Ltd is a privately held biopharmaceutical company advancing a proprietary platform of next-generation biologics called soloMERs. These engineered single-domain antibody-based molecules are designed to combine biologic precision with the localised activity of small molecules, drawing on an ADC-inspired conjugate strategy that the company believes can deliver safer and more effective treatment than conventional biologics alone. Lead Programme: ELN28 for Hidradenitis Suppurativa Elasmogen's lead clinical candidate, ELN28, is a first-in-class dual-acting soloMER conjugate targeting Hidradenitis Suppurativa (HS), a chronic and debilitating inflammatory skin condition characterised by painful lesions, deep nodules, abscesses, skin tunnels, and scarring. HS is recognised as a major unmet need: current treatments offer only partial benefit, and the disease carries a pronounced psychosocial burden in addition to its physical impact. ELN28 combines two clinically validated agents in a single construct, aiming to address both the inflammatory drivers and tissue pathology of HS with greater precision than existing monotherapies. Platform and Pipeline Ambitions Beyond HS, Elasmogen's soloMER platform has potential application across a broader range of immune-mediated inflammatory diseases and solid-tumour oncology indications. The company's stated vision is to lead the next wave of innovation in immune-mediated disease, developing therapies that redefine clinical practice. Elasmogen operates at the intersection of biologic drug development and novel conjugate chemistry, positioning the soloMER format as a modular, adaptable tool for addressing conditions where existing biologics fall short. Further information is available at elasmogen.com.

View profile
O

Owkin

Owkin applies federated learning and artificial intelligence to biomedical research, enabling pharmaceutical companies and academic medical centres to collaborate on sensitive patient data without that data ever leaving its source institution. Founded in 2016 and headquartered in New York, with significant operations in Paris, the company was built on the premise that the most clinically valuable datasets are also the most difficult to centralise, and that AI trained across distributed hospitals can outperform models trained on any single institution's records. The company's core platform, OwkinConnect, allows research partners to train AI models across federated networks of hospitals and research centres spanning Europe and North America. This approach has been applied most extensively to oncology, where Owkin has worked with academic partners to develop tissue-based biomarkers and patient stratification tools using digital pathology and multi-omic data. The company has established partnerships with major pharmaceutical groups and leading cancer centres including MSK and UCSF. Owkin operates at the intersection of software and drug discovery, licensing its AI-derived biomarkers and collaborating with biopharma partners on clinical trial design and patient selection. Its research outputs have been published in peer-reviewed journals, giving the platform academic as well as commercial credibility. The company has raised substantial venture funding from investors including Sanofi, which took a strategic stake, reflecting the pharmaceutical industry's appetite for federated AI capabilities. Further information is available at owkin.com.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy